PMID- 34916475
OWN - NLM
STAT- MEDLINE
DCOM- 20220413
LR  - 20220413
IS  - 1745-7262 (Electronic)
IS  - 1008-682X (Print)
IS  - 1008-682X (Linking)
VI  - 24
IP  - 2
DP  - 2022 Mar-Apr
TI  - Clinical application of free/total PSA ratio in the diagnosis of prostate cancer 
      in men over 50 years of age with total PSA levels of 2.0-25.0 ng ml(-1) in 
      Western China.
PG  - 195-200
LID - 10.4103/aja202182 [doi]
AB  - The goal of this study was to investigate the clinical application of free/total 
      prostate-specific antigen (F/T PSA) ratio, considering the new broad serum total 
      PSA (T-PSA) "gray zone" of 2.0-25.0 ng ml(-1) in differential diagnosis of 
      prostate cancer (PCa) and benign prostate diseases (BPD) in men over 50 years in 
      Western China. A total of 1655 patients were included, 528 with PCa and 1127 with 
      BPD. Serum T-PSA, free PSA (F-PSA), and F/T PSA ratio were analyzed. Receiver 
      operating characteristic curves were used to assess the efficiency of PSA and F/T 
      PSA ratio. There were 47.4% of cancer patients with T-PSA of 2.0-25.0 ng ml(-1). 
      When T-PSA was 2.0-4.0 ng ml(-1), 4.0-10.0 ng ml(-1), and 10.0-25.0 ng ml(-1), 
      the area under the curve (AUC) of F/T PSA ratio was 0.749, 0.769, and 0.761, 
      respectively. The best AUC of F/T PSA ratio was 0.811 when T-PSA was 2.0-25.0 ng 
      ml(-1), with a specificity of 0.732, a sensitivity of 0.788, and an optimal 
      cutoff value of 15.5%. The AUC of F/T PSA ratio in different age groups (50-59 
      years, 60-69 years, 70-79 years, and >/=80 years) was 0.767, 0.806, 0.815, and 
      0.833, respectively, and the best sensitivity (0.857) and specificity (0.802) 
      were observed in patients over 80 years. The T-PSA trend was in accordance with 
      the Gleason score, tumor node metastasis (TNM) stage, and American Joint 
      Committee on Cancer prognosis group. Therefore, the F/T PSA ratio can facilitate 
      the differential diagnosis of PCa and BPD in the broad T-PSA "gray zone". Serum 
      T-PSA can be a Gleason score and prognostic indicator.
FAU - Gao, Xue-Dan
AU  - Gao XD
AD  - Department of Laboratory Medicine/Research Center of Clinical Laboratory 
      Medicine, West China Hospital of Sichuan University, Chengdu 610041, China.
FAU - Miao, Qiang
AU  - Miao Q
AD  - Department of Laboratory Medicine/Research Center of Clinical Laboratory 
      Medicine, West China Hospital of Sichuan University, Chengdu 610041, China.
FAU - Zhang, Jun-Long
AU  - Zhang JL
AD  - Department of Laboratory Medicine/Research Center of Clinical Laboratory 
      Medicine, West China Hospital of Sichuan University, Chengdu 610041, China.
FAU - Zhai, Jian-Zhao
AU  - Zhai JZ
AD  - Department of Laboratory Medicine/Research Center of Clinical Laboratory 
      Medicine, West China Hospital of Sichuan University, Chengdu 610041, China.
FAU - Gui, Xue-Mei
AU  - Gui XM
AD  - Department of Laboratory Medicine, Nan'an Chinese Medicine Hospital, Chongqing 
      400060, China.
FAU - Cai, Yi-Han
AU  - Cai YH
AD  - Department of Laboratory Medicine/Research Center of Clinical Laboratory 
      Medicine, West China Hospital of Sichuan University, Chengdu 610041, China.
FAU - Niu, Qian
AU  - Niu Q
AD  - Department of Laboratory Medicine/Research Center of Clinical Laboratory 
      Medicine, West China Hospital of Sichuan University, Chengdu 610041, China.
FAU - Cai, Bei
AU  - Cai B
AD  - Department of Laboratory Medicine/Research Center of Clinical Laboratory 
      Medicine, West China Hospital of Sichuan University, Chengdu 610041, China.
LA  - eng
PT  - Journal Article
PL  - China
TA  - Asian J Androl
JT  - Asian journal of andrology
JID - 100942132
RN  - EC 3.4.21.77 (Prostate-Specific Antigen)
SB  - IM
MH  - Area Under Curve
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Prostate-Specific Antigen
MH  - *Prostatic Neoplasms/pathology
MH  - ROC Curve
MH  - Sensitivity and Specificity
PMC - PMC8887115
OTO - NOTNLM
OT  - free/total prostate-specific antigen ratio
OT  - gray zone prostate-specific antigen
OT  - prostate cancer
OT  - total prostate-specific antigen
COIS- None
EDAT- 2021/12/18 06:00
MHDA- 2022/04/14 06:00
PMCR- 2021/12/10
CRDT- 2021/12/17 06:14
PHST- 2021/12/18 06:00 [pubmed]
PHST- 2022/04/14 06:00 [medline]
PHST- 2021/12/17 06:14 [entrez]
PHST- 2021/12/10 00:00 [pmc-release]
AID - 332118 [pii]
AID - AJA-24-195 [pii]
AID - 10.4103/aja202182 [doi]
PST - ppublish
SO  - Asian J Androl. 2022 Mar-Apr;24(2):195-200. doi: 10.4103/aja202182.